ANTI-DARATUMUMAB ANTIBODY - ANVISA Registration 80134860308
Access comprehensive regulatory information for ANTI-DARATUMUMAB ANTIBODY in Brazil's medical device market through Pure Global AI's free database. This Risk Class II medical device is registered under ANVISA number 80134860308 and manufactured by MEDION DIAGNOSTICS GRIFOLS AG. The registration is held by GRIFOLS BRASIL LTDA with validity until currently active (VIGENTE).
This page provides complete technical specifications for this device, regulatory compliance details, 5 similar products found using AI-powered semantic search. Pure Global AI offers free access to over 100,000+ Brazilian medical device registrations, helping global MedTech companies navigate ANVISA regulations, identify competitors, and discover partnership opportunities efficiently.

Janaina dos Santos de Miranda
🇧🇷 Brazil Regulatory Expert
Need help with your Brazil registration?
Contact Pure Global Brazil TeamDevice Details
Registration Details
80134860308
25351458325202412
02513899000171
Company Information
Dates and Status
Feb 17, 2025
VIGENTE
09/18/2025 19:00:01
ANTI-INFLIXIMAB (IFX) ANTIBODIES
Quantum Blue® Anti-Infliximab
Not specified
80102512585
Sep 24, 2020
IMMUNOGLOBULIN G
IgG MONO
KOVALENT DO BRASIL LTDA
80115310068
Aug 14, 2006
ANTI-HUMAN GLOBULIN (COOMBS)
ID-DAT IgG1/IgG3
Not specified
80020690454
Jul 14, 2025
ANTI-HUMAN GLOBULIN (COOMBS)
ID-DAT IgG1/IgG3
DIAMED GMBH
80020690454
Jul 14, 2025
IMMUNOGLOBULIN G
ANTISORO ANTI-IgG PER
SEBIA S.A.
80416660035
May 17, 2010